Trade Report: Today, Cara Therapeutics’ (CARA) Buy Rating Reiterate at HC Wainwright

Today, Cara Therapeutics’ (CARA) Buy Rating Reiterate at HC Wainwright

Cara Therapeutics Inc. (NASDAQ:CARA)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald set a $24.00 price objective on Cara Therapeutics and gave the company a “buy” rating in a research report on Sunday, November 6th. Needham & Company LLC cut their target price on Cara Therapeutics from $27.00 to $23.00 and set a “buy” rating for the company in a research note on Sunday, August 7th. Stifel Nicolaus cut their target price on Cara Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, August 5th. Zacks Investment Research lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $16.00 target price on shares of Cara Therapeutics in a research note on Friday, September 23rd. Ten investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $22.41.

Cara Therapeutics (NASDAQ:CARA) traded down 3.91% during midday trading on Tuesday, reaching $9.83. 560,381 shares of the company traded hands. The company’s market cap is $268.18 million. The company has a 50-day moving average price of $8.56 and a 200-day moving average price of $6.62. Cara Therapeutics has a 12-month low of $4.26 and a 12-month high of $17.69.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.05. During the same period in the prior year, the firm earned ($0.19) earnings per share. On average, analysts predict that Cara Therapeutics will post ($1.78) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors raised its position in Cara Therapeutics by 5.6% in the third quarter. BlackRock Fund Advisors now owns 954,036 shares of the biopharmaceutical company’s stock valued at $7,966,000 after buying an additional 50,289 shares in the last quarter. Opaleye Management Inc. raised its position in Cara Therapeutics by 100.2% in the first quarter. Opaleye Management Inc. now owns 855,000 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 428,000 shares in the last quarter. Pictet Asset Management Ltd. raised its position in Cara Therapeutics by 564.9% in the second quarter. Pictet Asset Management Ltd. now owns 775,898 shares of the biopharmaceutical company’s stock valued at $5,012,000 after buying an additional 659,198 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Cara Therapeutics by 32.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 551,181 shares of the biopharmaceutical company’s stock valued at $4,602,000 after buying an additional 134,396 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Cara Therapeutics by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 513,382 shares of the biopharmaceutical company’s stock valued at $3,194,000 after buying an additional 163,772 shares in the last quarter. Hedge funds and other institutional investors own 49.06% of the company’s stock.

About Cara Therapeutics

Related posts

Leave a Comment